Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Feld

Showing results (421-430 of 451) with videos related to

Pageof 46
Sort By:
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
Gut|February 12, 2013
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis CYaron Rotman, Mazen Noureddin, Jordan J Feld, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The Lancet. Gastroenterology & Hepatology|May 12, 2020
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label studyJordan J Feld, Marcelo Cypel, Deepali Kumar, et al.
Hepatology (Baltimore, Md.)|November 4, 2025
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis BCalvin Q Pan, Samer Saadi, Marc G Ghany, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
Alimentary Pharmacology & Therapeutics|September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver DiseaseLesley A Patmore, Ivana Carey, Jordan J Feld, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Pageof 46

Showing results (421-430 of 451) with videos related to

Sort By:
Pageof 46
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
Gut|February 12, 2013
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis CYaron Rotman, Mazen Noureddin, Jordan J Feld, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The Lancet. Gastroenterology & Hepatology|May 12, 2020
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label studyJordan J Feld, Marcelo Cypel, Deepali Kumar, et al.
Hepatology (Baltimore, Md.)|November 4, 2025
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis BCalvin Q Pan, Samer Saadi, Marc G Ghany, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
Alimentary Pharmacology & Therapeutics|September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver DiseaseLesley A Patmore, Ivana Carey, Jordan J Feld, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Pageof 46